COMP <GO>
AKTX vs AEON // EV/EBITDA & P/E VALUATION
Akari Therapeutics plc ADS (NASDAQ) VS. AEON Biopharma Inc. (Class A) (NYSE) • 15-METRIC TALLY: AKTX 2
— AEON 1
■ METRIC PARITY
LAST: $8.00 (-13.04%) • MKT CAP: $18.3M
valuation
—
LAST: $0.29 (+11.36%) • MKT CAP: $17.4M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AKTX VS. AEON)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AKTX | AEON | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 1/9 | +1.00 | AKTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.0 | 53.6 | -6.66 | AEON | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $18.3M | $17.4M | $910.4K | AKTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AKTX REV | AEON REV | AKTX GROSS % | AEON GROSS % | AKTX FCF | AEON FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$10.6M | -$17.3M |
| FY 2024 | $0 | $0 | — | — | -$12.6M | -$20.3M |
| FY 2023 | $367.9K | — | — | — | -$16.4M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AKTX // BETA —
AEON // BETA —